david ettinger, md, talks about levels of pd-l1 expression and agent selection
Published 8 years ago • 60 plays • Length 0:47
Download video MP4
Download video MP3
Similar videos
-
0:58
david gandara, md,, discusses pd-l1 expression and selecting the appropriate agent in nsclc patients
-
0:35
david ettinger, md, talks about impact of immunotherapy in 1st line metastatic nsclc patients
-
1:11
david ettinger, md, provides practical advice related to pd-l1 testing in metastatic nsclc patients
-
0:35
david ettinger, md, on cost of therapy when choosing agents for late stage lung cancer patients
-
0:48
julie brahmer, md, on the level of pd-l1 expression in selecting the appropriate agent in nsclc
-
0:25
david ettinger, md, on choosing between immunotherapy and chemotherapy in metastatic nsclc patients
-
0:56
david ettinger, md, on the positioning of ramucirumab (cyramza) for nsclc
-
56:55
the abcs of dtc & variants: understanding key terms, concepts & initial diagnostic & treatment. 154
-
8:02
day in the life of a doctor (ft. liver disease and hypertensive emergency)
-
9:55
managing side effects of chemotherapy, with jyoti d. patel, md
-
44:53
innovations in biotech: killing disease and living longer
-
37:38
learn the basics of immunotherapy from david reardon, m.d.
-
24:54
future of interventional cardiology in next decade by dr david moliterno
-
8:57
how much is too much? molecular testing in crc
-
5:27
david eagle, md: talking to patients about the cost of cancer
-
0:31
david gandara, md, discusses pembrolizumab vs docetaxel for previously treated nsclc patients
-
0:46
clinical trials in lung cancer explained video
-
7:55
pd-l1 expression in bladder cancer
-
4:00
staff training and education
-
1:24
help for advanced lung cancer video
-
0:42
dr. mcdermott on targeting pd-1 and pd-l1 in kidney cancer
-
1:25
dr. mcdermott discusses pd-l1 expression in kidney cancer
Clip.africa.com - Privacy-policy